A5015795264- Cardiac Structural Anomalies and Repair
- Mechanical Circulatory Support Devices
- Cardiomyopathy and Myosin Studies
- Cardiac pacing and defibrillation studies
- Cardiovascular Effects of Exercise
- Cardiac Arrhythmias and Treatments
- Viral Infections and Immunology Research
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrest and Resuscitation
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Transplantation: Methods and Outcomes
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Eosinophilic Disorders and Syndromes
- Venous Thromboembolism Diagnosis and Management
- Renal Transplantation Outcomes and Treatments
- Neurogenetic and Muscular Disorders Research
- Cellular transport and secretion
- Congenital Heart Disease Studies
- Parathyroid Disorders and Treatments
- Hormonal Regulation and Hypertension
- Fuel Cells and Related Materials
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
Ionis Pharmaceuticals (United States)
2019-2025
University of California, San Diego
2017-2023
University of Colorado Anschutz Medical Campus
2022
University of Colorado Denver
2022
Azienda Sanitaria Universitaria Integrata di Trieste
2022
VA San Diego Healthcare System
2022
UC San Diego Health System
2018-2020
RELX Group (United States)
2019
Marche Polytechnic University
2013-2017
University of California San Diego Medical Center
2017
Background— Among patients with implantable pacemakers and defibrillators, subclinical atrial fibrillation (SCAF) is associated an increased risk of stroke; however, there limited understanding their temporal relationship. Methods Results— The Asymptomatic Atrial Fibrillation Stroke Evaluation in Pacemaker Patients the Reduction Pacing Trial (ASSERT) enrolled 2580 pacemaker defibrillator aged ≥65 years a history hypertension but without fibrillation. Pacemakers cardioverter-defibrillators...
Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) 168 adults with Coutinho stage 1 or 2 polyneuropathy, Neuropathy Impairment Score...
Targeting angiotensinogen (AGT) may provide a novel approach to more optimally inhibit the renin-angiotensin-aldosterone system pathway. Double-blind, placebo-controlled clinical trials were performed in subjects with hypertension as monotherapy or an add-on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers IONIS-AGT-LRx versus placebo up 2 months. was well tolerated no significant changes platelet count, potassium levels, liver and renal function. significantly reduced...
AAV9.LAMP2B corrects metabolic and physiologic manifestations of a murine model Danon disease.
AKCEA-TTR-LRx is a ligand-conjugated antisense (LICA) drug in development for the treatment of hereditary transthyretin amyloidosis (hATTR), fatal disease caused by mutations (TTR) gene. shares same nucleotide sequence as inotersen, an medicine approved use hATTR polyneuropathy (hATTR-PN). Unlike conjugated to triantennary N-acetylgalactosamine moiety that supports receptor-mediated uptake hepatocytes, primary source circulating TTR. This advanced design increases potency allow lower and...
Atrial fibrillation (AF) is associated with a wide range of clinical presentations. Whether and how AF symptoms can affect prognosis still unclear. Aims the present analysis were to investigate potential predictors symptomatic determine if are higher incidence cardiovascular (CV) events at 1-year follow-up.The Euro Heart Survey on Fibrillation included 3607 consecutive patients documented available follow-up regarding status. Patients found baseline classified into (SS group; n = 896)...
Cardiac resynchronization therapy (CRT) improves symptoms and reduces mortality in heart failure (HF) patients, but little data exist on the efficacy of CRT elderly. The aim our study is to define CRT-related benefits terms left ventricular ejection fraction (LVEF) improvement two subgroups patients (<75 ≥75 years old) test possible differences between these groups. Single-centre prospective observational including 65 with optimally treated, advanced HF indication CRT. All were investigated...